Navigation Links
Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
Date:11/16/2009

BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is participating in the 38(th) Annual American Association of Gynecologic Laparoscopists (AAGL) conference, November 15-19, 2009 in Orlando, Florida, and will feature its Adiana(®) permanent contraception system.

Adiana is a minimally invasive procedure that requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. The Adiana system is designed to provide women a minimally invasive alternative to traditional, surgical means of permanent contraception. With the Adiana system, patients are normally able to return to work or resume their daily activities within one day. In contrast, traditional methods of permanent contraception, such as tubal ligation, require more invasive surgical procedures, usually are conducted in a hospital under general anesthesia, and typically require four to five days of recovery.

"AAGL is the most influential meeting for physicians providing patient care through minimally invasive gynecology," said Tony Kingsley, senior vice president, GYN surgical products at Hologic. "As we have learned through numerous patient testimonials, women are undergoing the Adiana procedure to seek relief from the uncertainty and hassle of temporary birth control methods. At Hologic, we continue to bring to market tools that allow physicians to offer women in-office alternatives for their long-term contraception and other gynecological needs."

At AAGL, physicians will present open communication sessions and poster presentations on the Adiana system and the hysteroscopic sterilization method used during the Adiana procedure. Primary investigators will present new data from studies on the Adiana system.

Approved by the Food and Drug Administration (FDA) in July 2009, the Adiana procedure is indicated for women who desire permanent birth control by occlusion of the fallopian tubes.

Ideal candidates include women who do not want children in the future and would like the peace of mind and convenience of permanent birth control.

Sessions for information and key findings about Adiana at AAGL include:

  • "Adiana System for Transcervical Sterilization: 3-Year Efficacy Results;" presented by T.L. Anderson, T.G. Vancaillie; Open Communications; 6 -- Hysteroscopy (Wednesday, 11/18 at 11:48 pm)
  • "Mechanism of Action of the Adiana Device: A Histologic Perspective;" presented by T.G. Vancaillie, D. Harrington, V. Carr-Brendel, J. Anderson; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:44 pm)
  • "Evaluating the Learning Curve for a Novel Hysteroscopic Sterilization Technique;" presented by M.Y. Bongers, S. Veersema; Open Communications; 16 -- Hysteroscopy (Thursday, 11/19 at 8:12 am)
  • "Feasibility of Hysterosalpingography To Evaluate Tubal Occlusion Following Concomitant Adiana(®) Transcervical Sterilization and NovaSure(®) Endometrial Ablation;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Poster Presentation
  • "Concominant Use of Adiana(®) Permanent Contraception and NovaSure(®) Impedance Controlled Endometrial Ablation: A Peri-Hysterectomy Study;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:26 pm)

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Adiana permanent contraception system. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Adiana permanent contraception system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic, Adiana and NovaSure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Contact:  Stephanie Cilibrasi                          Anne Rivers
              Product Manager, Adiana Product Marketing    Corporate Marketing
              Hologic, Inc.                                Hologic, Inc.
              (339) 221-3292                               (508) 263-8765
              Email: adianamedia@hologic.com

SOURCE Hologic, Inc.


'/>"/>
SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... 16, 2017 , ... Richard Strawn’s new book Surgical ... of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and hope, ... God shows love to those who are sick., Surgical Psalms contains 36 reflections ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
Breaking Medicine News(10 mins):